Archive


Category: Everest Medicines

  • Gilead moves closer to Chinese filing for Trodelvy in TNBC

    Gilead Sciences’ Trodelvy has met its objectives in a phase 2b trial in triple-negative breast cancer (TNBC) carried out in China by its partner Everest Medicines, moving it closer to a regulatory filing in the world’s second-largest pharma market. Antibody-drug conjugate Trodelvy (sacituzumab govitecan) is already approved in the US for TNBC, and was licensed […]